Pharma Mar Forecast, price target & analysts
Pharma Mar Target price 2026 - Analyst rating & recommendation
Pharma Mar Classifications & Recommendation
Pharma Mar Price Target
| Target Price | €99.96 |
| Price | €75.00 |
| Potential |
33.28%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Pharma Mar 2027 .
The average Pharma Mar target price is €99.96.
This is
33.28%
register free of charge
€131.25
75.00%
register free of charge
€63.29
15.62%
register free of charge
|
|
| A rating was issued by 14 analysts: 10 Analysts recommend Pharma Mar to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pharma Mar stock has an average upside potential 2027 of
33.28%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million € | 221.39 | 211.02 |
| 26.61% | 4.68% | |
| EBITDA Margin | 29.84% | 27.01% |
| 389.07% | 9.49% | |
| Net Margin | 33.87% | 22.86% |
| 126.67% | 32.51% |
11 Analysts have issued a sales forecast Pharma Mar 2026 . The average Pharma Mar sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Pharma Mar EBITDA forecast 2026. The average Pharma Mar EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Pharma Mar Analysts have issued a net profit forecast 2026. The average Pharma Mar net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | 4.30 | 2.78 |
| 188.59% | 35.35% | |
| P/E | 26.96 | |
| EV/Sales | 5.83 |
11 Analysts have issued a Pharma Mar forecast for earnings per share. The average Pharma Mar EPS is
This results in the following potential growth metrics and future valuations:
Current Pharma Mar Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BANCO SANTANDER |
Locked
➜
Locked
|
Locked | Jul 06 2026 |
| RX SECURITIES |
Locked
➜
Locked
|
Locked | Jun 22 2026 |
| CHARDAN CAPITAL MARKETS |
Locked
➜
Locked
|
Locked | Jun 14 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jun 14 2026 |
| NEEDHAM & COMPANY INC. |
Locked
➜
Locked
|
Locked | Jun 14 2026 |
| ALANTRA EQUITIES |
Locked
➜
Locked
|
Locked | Jun 11 2026 |
| BESTINVER SECURITIES |
Locked
➜
Locked
|
Locked | Jun 01 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BANCO SANTANDER:
Locked
➜
Locked
|
Jul 06 2026 |
|
Locked
RX SECURITIES:
Locked
➜
Locked
|
Jun 22 2026 |
|
Locked
CHARDAN CAPITAL MARKETS:
Locked
➜
Locked
|
Jun 14 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jun 14 2026 |
|
Locked
NEEDHAM & COMPANY INC.:
Locked
➜
Locked
|
Jun 14 2026 |
|
Locked
ALANTRA EQUITIES:
Locked
➜
Locked
|
Jun 11 2026 |
|
Locked
BESTINVER SECURITIES:
Locked
➜
Locked
|
Jun 01 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
